Literature DB >> 25305076

Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's disease.

Brett A Barbaro1, Tamas Lukacsovich1, Namita Agrawal2, John Burke1, Doug J Bornemann1, Judith M Purcell1, Shane A Worthge1, Andrea Caricasole3, Andreas Weiss3, Wan Song1, Olga A Morozova4, David W Colby4, J Lawrence Marsh5.   

Abstract

Although Huntington's disease is caused by the expansion of a CAG triplet repeat within the context of the 3144-amino acid huntingtin protein (HTT), studies reveal that N-terminal fragments of HTT containing the expanded PolyQ region can be produced by proteolytic processing and/or aberrant splicing. N-terminal HTT fragments are also prevalent in postmortem tissue, and expression of some of these fragments in model organisms can cause pathology. This has led to the hypothesis that N-terminal peptides may be critical modulators of disease pathology, raising the possibility that targeting aberrant splicing or proteolytic processing may present attractive therapeutic targets. However, many factors can contribute to pathology, including genetic background and differential expression of transgenes, in addition to intrinsic differences between fragments and their cellular effects. We have used Drosophila as a model system to determine the relative toxicities of different naturally occurring huntingtin fragments in a system in which genetic background, transgene expression levels and post-translational proteolytic processing can be controlled. These studies reveal that among the naturally occurring N-terminal HTT peptides, the exon 1 peptide is exceptionally pathogenic and exhibits unique structural and biophysical behaviors that do not appear to be incremental changes compared with other fragments. If this proves correct, efforts to specifically reduce the levels of exon 1 peptides or to target toxicity-influencing post-translational modifications that occur with the exon 1 context are likely to have the greatest impact on pathology.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25305076      PMCID: PMC4834878          DOI: 10.1093/hmg/ddu504

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  48 in total

1.  A guided tour into subcellular colocalization analysis in light microscopy.

Authors:  S Bolte; F P Cordelières
Journal:  J Microsc       Date:  2006-12       Impact factor: 1.758

2.  Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila.

Authors:  Namita Agrawal; Judit Pallos; Natalia Slepko; Barbara L Apostol; Laszlo Bodai; Ling-Wen Chang; Ann-Shyn Chiang; Leslie Michels Thompson; J Lawrence Marsh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

3.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

Review 4.  Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches.

Authors:  C L Wellington; M R Hayden
Journal:  Clin Genet       Date:  2000-01       Impact factor: 4.438

5.  Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila.

Authors:  J L Marsh; H Walker; H Theisen; Y Z Zhu; T Fielder; J Purcell; L M Thompson
Journal:  Hum Mol Genet       Date:  2000-01-01       Impact factor: 6.150

6.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

Review 7.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

8.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Authors:  J S Steffan; L Bodai; J Pallos; M Poelman; A McCampbell; B L Apostol; A Kazantsev; E Schmidt; Y Z Zhu; M Greenwald; R Kurokawa; D E Housman; G R Jackson; J L Marsh; L M Thompson
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

9.  Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.

Authors:  Ivelisse Sánchez; Christian Mahlke; Junying Yuan
Journal:  Nature       Date:  2003-01-23       Impact factor: 49.962

10.  Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Christian Landles; Andreas Weiss; Sophie Franklin; David Howland; Gill Bates
Journal:  PLoS Curr       Date:  2012-07-16
View more
  26 in total

1.  Structural Mechanisms of Mutant Huntingtin Aggregation Suppression by the Synthetic Chaperonin-like CCT5 Complex Explained by Cryoelectron Tomography.

Authors:  Michele C Darrow; Oksana A Sergeeva; Jose M Isas; Jesús G Galaz-Montoya; Jonathan A King; Ralf Langen; Michael F Schmid; Wah Chiu
Journal:  J Biol Chem       Date:  2015-05-20       Impact factor: 5.157

2.  Abrogation of prenucleation, transient oligomerization of the Huntingtin exon 1 protein by human profilin I.

Authors:  Alberto Ceccon; Vitali Tugarinov; Rodolfo Ghirlando; G Marius Clore
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-03       Impact factor: 11.205

Review 3.  Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.

Authors:  Sweta Shah; Marc Marie Dooms; Sofia Amaral-Garcia; Mariana Igoillo-Esteve
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

4.  Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties.

Authors:  Nathan Riguet; Anne-Laure Mahul-Mellier; Niran Maharjan; Johannes Burtscher; Marie Croisier; Graham Knott; Janna Hastings; Alice Patin; Veronika Reiterer; Hesso Farhan; Sergey Nasarov; Hilal A Lashuel
Journal:  Nat Commun       Date:  2021-11-12       Impact factor: 14.919

Review 5.  Prion-like properties of the mutant huntingtin protein in living organisms: the evidence and the relevance.

Authors:  Melanie Alpaugh; Hélèna L Denis; Francesca Cicchetti
Journal:  Mol Psychiatry       Date:  2022-01       Impact factor: 15.992

Review 6.  Studying polyglutamine diseases in Drosophila.

Authors:  Zhen Xu; Antonio Joel Tito; Yan-Ning Rui; Sheng Zhang
Journal:  Exp Neurol       Date:  2015-08-06       Impact factor: 5.330

7.  Effects of flanking sequences and cellular context on subcellular behavior and pathology of mutant HTT.

Authors:  Anjalika Chongtham; Douglas J Bornemann; Brett A Barbaro; Tamas Lukacsovich; Namita Agrawal; Adeela Syed; Shane Worthge; Judith Purcell; John Burke; Theodore M Chin; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2020-03-13       Impact factor: 6.150

8.  Folding Landscape of Mutant Huntingtin Exon1: Diffusible Multimers, Oligomers and Fibrils, and No Detectable Monomer.

Authors:  Bankanidhi Sahoo; Irene Arduini; Kenneth W Drombosky; Ravindra Kodali; Laurie H Sanders; J Timothy Greenamyre; Ronald Wetzel
Journal:  PLoS One       Date:  2016-06-06       Impact factor: 3.240

9.  The Enemy within: Innate Surveillance-Mediated Cell Death, the Common Mechanism of Neurodegenerative Disease.

Authors:  Robert I Richards; Sarah A Robertson; Louise V O'Keefe; Dani Fornarino; Andrew Scott; Michael Lardelli; Bernhard T Baune
Journal:  Front Neurosci       Date:  2016-05-10       Impact factor: 4.677

10.  The phasor-FLIM fingerprints reveal shifts from OXPHOS to enhanced glycolysis in Huntington Disease.

Authors:  Sara Sameni; Adeela Syed; J Lawrence Marsh; Michelle A Digman
Journal:  Sci Rep       Date:  2016-10-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.